MarketCap
Facebook
X
Telegram
Biogen Accounts Receivables | BIIB
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.34 B | 1.4 B | 1.66 B | 1.7 B | 1.55 B | 1.91 B | 1.88 B | 1.96 B | 1.79 B | 1.44 B | 1.23 B | 1.29 B | 824 M | 687 M | 585 M | 605 M | 551 M | 447 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 B | 447 M | 1.27 B |
Quarterly Accounts Receivables Biogen
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 1.63 B | 1.7 B | 1.57 B | 1.57 B | 1.63 B | 1.55 B | 1.72 B | 1.69 B | 1.55 B | 1.91 B | 1.91 B | 1.91 B | 1.91 B | 1.88 B | 1.88 B | 1.88 B | 1.88 B | 1.96 B | 1.96 B | 1.96 B | 1.96 B | 1.79 B | 1.79 B | 1.79 B | 1.79 B | 1.44 B | 1.44 B | 1.44 B | 1.44 B | 1.23 B | 1.23 B | 1.23 B | 1.23 B | 1.29 B | 1.29 B | 1.29 B | 1.29 B | 824 M | 824 M | 824 M | 824 M | 687 M | 687 M | 687 M | 687 M | 585 M | 585 M | 585 M | 585 M | 617 M | 549 M | 561 M | 551 M | 511 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 B | 511 M | 1.33 B |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
73.6 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
405 K | - | 1.32 % | $ 16.2 M |  USA |
 |
Dynavax Technologies Corporation
DVAX
|
45.3 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Qilian International Holding Group Limited
QLI
|
4.25 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
437 K | - | 1.35 % | $ 17.8 M | China |
 |
Codexis
CDXS
|
10 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
71.8 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
Assembly Biosciences
ASMB
|
974 K | $ 36.6 | 1.3 % | $ 410 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
2.24 M | - | -1.58 % | $ 28.1 M | China |
 |
Generation Bio Co.
GBIO
|
1.22 M | - | - | $ 344 M | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
18 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
33.8 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
2.04 M | $ 4.3 | 1.42 % | $ 298 M |  Britain |
 |
ChromaDex Corporation
CDXC
|
9.74 M | - | -0.88 % | $ 598 M | USA |